Since immunotherapy regimens most commonly employ monoclonal antibodies targeting regulatory checkpoints [13], we determined the expression levels of four immune checkpoints (CTLA4, LAG3, PD1, and TIM3) on tumor infiltrating T cells, and PD-L1 expression on B6CaP tumor cells. This evidence concerns the gene LAG3 and neoplasm.